AKR1C1 and nasopharyngeal carcinoma: Zhou et al. discovered that cisplatin sensitivity was increased in ARK1C1-silenced NPC cells and advocated for further studies to validate AKR1C1 as a marker for predicting response to cisplatin in patients with NPC [149].